IPH.PA stock is trading intraday at €1.17, up 8.94% as traders position ahead of Innate Pharma S.A.’s scheduled earnings release later this week. The biotech moves on low float and active volume of 408,020 shares versus an average of 166,477. Market focus will be on clinical development updates for Monalizumab and Lacutamab and any guidance on partnerships or cash runway. We examine valuation, running catalysts, and short-term trade setups before the 26 Mar 2026 announcement.
IPH.PA stock: earnings timeline and near-term catalysts
Innate Pharma reports earnings after the market on 26 Mar 2026, with the company expected to update on Phase III Monalizumab progress and cash position. Investors will watch commentary on trial enrollment, upcoming readouts, and partnership milestones that could shift revenue timelines.
The stock has a tight trading range today between €1.03 and €1.19, and we expect intraday moves to accelerate on any headline from management or trial sponsors. Volume today is 408,020, a 2.45x relative volume signal versus the 166,477 average.
IPH.PA stock: clinical program impact on revenue outlook
Innate Pharma’s pipeline — including Monalizumab (Phase III) and Lacutamab (Phase II) — is the main driver of long-term upside. Positive Phase III signals could materially affect licensing discussions with partners such as AstraZeneca and Sanofi, improving revenue visibility.
Near-term financial readthrough will be limited; current revenue per share is €0.15 and EPS is -0.55, underscoring a development-stage business model. Any management update on milestone timing or new partner payments would be the key earnings takeaway.
IPH.PA stock: valuation, cash and key financial metrics
At €1.17, Innate Pharma’s market cap is €109,681,437 with 93,744,818 shares outstanding. Price averages sit at €1.43 (50-day) and €1.63 (200-day). The company shows a high PB ratio of 19.42 and a negative PE of -2.13, reflecting ongoing losses.
Liquidity metrics show a current ratio of 2.21 and cash per share of €0.70, indicating a modest cash buffer. Debt-to-equity is elevated at 5.25, so cash runway comments in the earnings call will matter for near-term financing risk.
IPH.PA stock: technical and trading setup
Technically, IPH.PA is oversold on several momentum indicators: RSI 34.99, CCI -101.16, and Stochastic %K 13.04. Bollinger Bands place a lower band at €1.07 and upper at €1.58, suggesting room for a mean reversion if news is positive.
Short-term traders should note the high relative volume today (relVolume 2.45) and an ADX of 35.45, signalling a strong trend. Tight stops are advisable given a recent 1-year decline of -35.71% and a 3-month slide of -23.03%.
IPH.PA stock: Meyka AI grade and model forecast
Meyka AI rates IPH.PA with a score out of 100: 63.11 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Meyka AI’s forecast model projects a yearly price of €1.39, compared with the current €1.17, implying an 18.80% upside. Monthly and quarterly model points are €1.14 and €1.41 respectively. Forecasts are model-based projections and not guarantees.
IPH.PA stock: risks, partnerships and sector context
Key risks include trial setbacks, higher-than-expected cash burn, and dilution if management raises capital. Innate sits in Europe Healthcare / Biotechnology where sector YTD performance is down -6.47%, increasing downside sensitivity for small caps.
Opportunities hinge on positive clinical updates or milestone payments from partners. Keep an eye on licensing language in the report and any guidance on milestone timing for 2026 and 2027.
Final Thoughts
Short-term trading in IPH.PA stock will pivot on the 26 Mar 2026 earnings release and any clinical updates for Monalizumab and Lacutamab. At €1.17, the market is pricing substantial development risk; core metrics show EPS -0.55, PB 19.42, and elevated debt-to-equity at 5.25. Meyka AI’s model projects a yearly price of €1.39, implying an 18.80% upside versus current levels, while the 50-day and 200-day averages of €1.43 and €1.63 set technical resistance. For investors, the outlook is event-driven: positive trial language or partner milestones could validate a base case near €1.40, while material setbacks or funding needs would increase downside toward €0.90 in a bear scenario. We recommend monitoring the earnings call for explicit cash runway commentary and milestone timing, and using tight risk controls in intraday trading. Meyka AI provides this as AI-powered market analysis; forecasts and grades are model outputs, not investment advice.
FAQs
When does Innate Pharma report earnings and why does it matter for IPH.PA stock?
Innate Pharma reports after market on 26 Mar 2026. The earnings call may reveal trial progress, partnership milestones, and cash runway, all of which directly affect IPH.PA stock volatility and near-term valuation.
What is Meyka AI’s forecast for IPH.PA stock and how should I use it?
Meyka AI’s forecast model projects a yearly price of €1.39 for IPH.PA stock, implying an 18.80% upside from €1.17. Use this as a model-based projection, not a guaranteed outcome, and combine it with fundamental analysis.
What are the main financial risks for IPH.PA stock after earnings?
Key risks include negative EPS (currently -0.55), high debt-to-equity of 5.25, and potential dilution if Innate Pharma needs to raise capital. Earnings commentary on cash and milestones will be critical.
Which clinical programs will most influence IPH.PA stock in the report?
Monalizumab (Phase III) and Lacutamab (Phase II) are the primary drivers. Positive updates or clarified timelines for these programs would be the strongest near-term catalysts for IPH.PA stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)